Epstein-Barr Virus

Principles and Practice of Clinical Virology: Sixth Edition

Volumn , Issue , 2009, Pages 199-221

  Haque, Tanzina ^a   Crawford, Dorothy H ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Burkitt's lymphoma (BL); Chronic active EBV (CAEBV) infection; EB Viral Nuclear Antigens (EBNAs); EBV infection in immunocompromised host; EBV coded latent proteins and latent transcripts in diseases; EBV induced B Cell transformation and immortalization; Epstein Barr virus (EBV); Vaccine development; Viral coded proteins and transcripts

Indexed keywords

EID: 84890720494     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470741405.ch9     Document Type: Chapter

References (78)

1. Anagnostopoulos, I., Herbst, H., Niedobitek, G. et al. (1989) Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood, 74, 810-16.
2. Anagnostopoulos, I., Hummel, M., Kreschel, C. et al. (1995) Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood, 85, 744-50.
3. Baer, R., Bankier, A.T., Biggin, M.D. et al. (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature, 310, 207-11.
4. Bell, A.I., Groves, K., Kelly, G.L. et al. (2006) Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. The Journal of General Virology, 87, 2885-90.
5. Borza, C.M. and Hutt-Fletcher, L.M. (2002) Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nature Medicine, 8, 594-99.
6. Burkitt, D. (1958) A sarcoma involving the jaws in African children. The British Journal of Surgery, 46, 218-23.
7. Burns, D.M. and Crawford, D.H. (2004) Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Reviews, 18, 193-209.
8. Callan, M.F., Steven, N., Krausa, P. et al. (1996) Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nature Medicine, 2, 906-11.
9. Choquet, S., Leblond, V., Herbrecht, R. et al. (2006) Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 107 (8), 3053-7.
10. Coffey, A.J., Brooksbank, R.A., Brandau, O. et al. (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genetics, 20, 129-35.
11. Crawford, D.H., Macsween, K.F., Higgins, C.D. et al. (2006) A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clinical Infectious Diseases, 43, 276-82.
12. Crawford, D.H., Swerdlow, A.J. and Higgins, C. (2002) Sexual history and Epstein-Barr virus infection. The Journal of Infectious Diseases, 186, 731-36.
13. Crawford, D.H., Thomas, J.A., Janossy, G. et al. (1980) Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet, 1, 1355-56.
14. Dawson, C.W., Rickinson, A.B. and Young, L.S. (1990) Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature, 344, 777-80.
15. De Jesus, O., Smith, P.R. and Spender, L.C. (2003) Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. The Journal of General Virology, 84, 1443-50.
16. Diepstra, A., Niens, M., Vellenga, E. et al. (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet, 365, 2216-24.
17. Downey, H., McKinlay, C.A. (1923) Acute lymphadenosis compared with acute lymphatic leukaemia. Archives of Internal Medicine, 32, 82-112.
18. Epstein, M.A. (1984) The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours. Proceedings of the Royal Society of London. Series B: Biological Sciences, 221, 1-20.
19. Epstein, M.A., Achong, B. and Barr, Y. (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 15, 702-3.
20. Epstein, M.A. and Barr, Y. (1964) Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Lancet, 1, 252-53.
21. Gaspar, H.B., Sharifi, R., Gilmour, K.C. et al. (2002) X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. British Journal of Haematology, 119, 585-95.
22. Greenspan, J.S., Greenspan, D., Lennette, E.T. et al. (1985) Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDSassociated lesion. The New England Journal of Medicine, 313, 1564-71.
23. Haque, T., Thomas, J.A., Parratt, R. et al. (1997) A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation, 64, 1028-34.
24. Haque, T., Wilkie, G.M., Taylor, C. et al. (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLAmatched allogeneic cytotoxic T cells. Lancet, 360, 436-42.
25. Haque, T., Wilkie, G.M., Jones, M.M. et al. (2007) Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lymphoproliferative disease: results of a phase II multicentre clinical trial. Blood, 110, 1123-31.
26. Henle, G. and Henle, W. (1966) Immunofluorescence in cells derived from Burkitt's lymphoma. Journal of Bacteriology, 91, 1248-56.
27. Henle, G., Henle, W. and Klein, G. (1971) Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. International Journal of Cancer, 8, 272-82.
28. Hochberg, D., Middeldorp, J.M. and Catalina, M. (2004) Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 101, 239-44.
29. Imai, S., Koizumi, S., Sugiura, M. et al. (1994) Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proceedings of the National Academy of Sciences of the United States of America, 91, 9131-35.
30. Israele, V., Shirley, P. and Sixbey, J.W. (1991) Excretion of the Epstein-Barr virus from the genital tract of men. The Journal of Infectious Diseases, 163, 1341-43.
31. Jarrett, R.F. (2002) Viruses and Hodgkin's lymphoma. Annals of Oncology, 13 (Suppl 1), 23-29.
32. Johannsen, E., Koh, E., Mosialos, G. et al. (1995) Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. Journal of Virology, 69, 253-62.
33. Jones, J.F., Shurin, S., Abramowsky, C. et al. (1988) T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. The New England Journal of Medicine, 318, 733-41.
34. Kennedy, G., Komano, J. and Sugden, B. (2003) Epstein- Barr virus provides a survival factor to Burkitt's lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 100, 14269-74.
35. Kimura, H. (2006) Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Reviews in Medical Virology, 16, 251-61.
36. Kirk, O., Pedersen, C., Cozzi-Lepri, A. et al. (2001) Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood, 98, 3406-12.
37. Kitagawa, N., Goto, M., Kurozumi, K. et al. (2000) Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO Journal, 19, 6742-50.
38. Komano, J., Maruo, S., Kurozumi, K. et al. (1999) Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. Journal of Virology, 73, 9827-31.
39. Lee, E.S., Locker, J., Nalesnik, M. et al. (1995) The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. The New England Journal of Medicine, 332, 19-25.
40. Lee, T.C., Savoldo, B., Rooney, C.M. et al. (2005) Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. American Journal of Transplantation, 5, 2222-28.
41. Leyvraz, S., Henle, W., Chahinian, A.P. et al. (1985) Association of Epstein-Barr virus with thymic carcinoma. The New England Journal of Medicine, 312, 1296-99.
42. Lu, C.C., Chen, J.C., Tsai, S.T. et al. (2005) Nasopharyngeal carcinoma-susceptibility locus is localized to a 132kb segment containing HLA-A using high-resolution microsatellite mapping. International Journal of Cancer, 115, 742-46.
43. Luka, J., Kallin, B. and Klein, G. (1979) Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology, 94, 228-31.
44. Marafioti, T., Hummel, M., Foss, H.D. et al. (2000) Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood, 95, 1443-50.
45. McAulay, K., Higgins, C.D., Macsween, K.F. et al. (2007) HLA class I polymorphisms are significantly associated with infectious mononucleosis. The Journal of Clinical Investigation, 117, 3042-8.
46. Mettenleiter, T.C., Klupp, B.G. and Granzow, H. (2006) Herpesvirus assembly: a tale of two membranes. Current Opinion in Microbiology, 9, 423-29.
47. Miller, G., Shope, T. and Lisco, H. (1972) Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proceedings of the National Academy of Sciences of the United States of America, 69, 383-87.
48. Miller, C.L., Burkhardt, A.L., Lee, J.H. et al. (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases Immunity, 2, 155-66.
49. Morrison, J.A., Klingelhutz, A.J. and Raab-Traub, N. (2003) Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. Journal of Virology, 77, 12276-84.
50. Moutschen, M., Leonard, P., Sokal, E.M. et al. (2007) Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine, 25, 4697-705.
51. Nakagawa, M., Hashino, S., Takahata, M. et al. (2007) Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active Epstein-Barr virus infection. International Journal of Hematology, 85, 443-45.
52. Nanbo, A., Inoue, K., chi-Takasawa, K. et al. (2002) Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO Journal, 21, 954-65.
53. Nichols, K.E., Harkin, D.P., Levitz, S. et al. (1998) Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proceedings of the National Academy of Sciences of the United States of America, 95, 13765-70.
54. Niederman, J.C., Evans, A.S., Subrahmanyan, L. et al. (1970) Prevalence, incidence and persistence of EB virus antibody in young adults. The New England Journal of Medicine, 282, 361-65.
55. Old, L.J., Boyse, E.A., Oettgen, H.F. et al. (1966) Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 56, 1699-704.
56. Opelz, G., Daniel, V., Naujokat, C. et al. (2007) Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. The Lancet Oncology, 8, 212-18.
57. Pfeffer, S., Zavolan, M., Grasser, F.A. et al. (2004) Identification of virus-encoded microRNAs. Science, 304, 734-36.
58. Purtilo, D.T., Cassel, C. and Yang, J.P. (1974) Letter: fatal infectious mononucleosis in familial lymphohistiocytosis. The New England Journal of Medicine, 291, 736.
59. Raab-Traub, N., Rajadurai, P., Flynn, K. et al. (1991) Epstein-Barr virus infection in carcinoma of the salivary gland. Journal of Virology, 65, 7032-36.
60. Rao, C.R., Gutierrez, M.I., Bhatia, K. et al. (2000) Association of Burkitt's lymphoma with the Epstein-Barr virus in two developing countries. Leukemia and Lymphoma, 39, 329-37.
61. Rechsteiner, M.P., Berger, C., Weber, M. et al. (2007) Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells. The Journal of General Virology, 88, 1454-59.
62. Reedman, B.M. and Klein, G. (1973) Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and nonproducer lymphoblastoid cell lines. International Journal of Cancer, 11, 499-520.
63. Rooney, C.M., Smith, C.A., Ng, C.Y. et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-55.
64. Savoldo, B., Huls, M.H., Liu, Z. et al. (2002) Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood, 100, 4059-66.
65. Sayos, J., Wu, C. and Morra, M. (1998) The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature, 395, 462-69.
66. Sixbey, J.W., Lemon, S.M. and Pagano, J.S. (1986) A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet, 2, 1122-24.
67. Takada, K. (1984) Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. International Journal of Cancer, 33, 27-32.
68. Timms, J.M., Bell, A., Flavell, J.R. et al. (2003) Target cells of Epstein-Barr-virus (EBV)-positive posttransplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet, 361, 217-23.
69. Tokunaga, M., Land, C.E., Uemura, Y. et al. (1993) Epstein-Barr virus in gastric carcinoma. American Journal of Pathology, 143, 1250-54.
70. Tugizov, S., Herrera, R., Veluppillai, P. et al. (2007) Epstein-Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium. Journal of Virology, 81, 5484-96.
71. Wang, F., Gregory, C., Sample, C. et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. Journal of Virology, 64, 2309-18.
72. Wang, D., Liebowitz, D. and Kieff, E. (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell, 43, 831-40.
73. Wilson, J.B., Bell, J.L. and Levine, A.J. (1996) Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO Journal, 15, 3117-26.
74. Wilson, J.B., Weinberg, W., Johnson, R. et al. (1990) Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell, 61, 1315-27.
75. Wolf, H., zur Hausen, H. and Becker, V. (1973) EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nature: New Biology, 244, 245-47.
76. Young, L.S. and Murray, P.G. (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene, 22, 5108-121.
77. zur-Hausen, H., O'Neill, F.J., Freese, U.K. et al. (1978) Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature, 272, 373-75.
78. zur-Hausen, H., Bornkamm, G.W., Schmidt, R., Hecker, E. (1979) Tumor initiators and promoters in the induction of Epstein-Barr virus. Proceedings of the National Academy of Sciences of the United States of America, 76 (2), 782-5.